Seven High-Profile Companies in GenTrust Healthcare Ecosystem — Tansino Biosciences, Topcon Medical, Xinkanghe Bio, Rosendorf Robotics, Chenglian Tech, Genecast Biotech, and Henlius — File IPO Prospectuses Amid Major Clinical and Commercial Milestones

Oct 14, 2025 13:25 CST Updated 13:25

Mabworks

Differentiated Antibody Drug Developer

TowardPi

High-end Ophthalmic Medical Device Developer

▲ The 15th issue of GaoTJ Insights, the industry research publication by GaoTJ, has been officially released. The core research report focuses on AI in healthcare, providing an in-depth analysis of how AI technology is driving medical research and clinical applications toward a new paradigm. Multiple members of the GaoTJ ecosystem were invited to discuss their experiences, innovations, and practices in AI healthcare.

Recently, members of the Gao Tejia Healthcare EcosystemBeijing Mabworks Biotechnology Co.,Ltd, TowardPi (Beijing) Medical Technology Co.,Ltd, Xinkanghe Bio, Rosenbott, Chenglian Technology, Kunyuan Bio, HenliusAchieved multiple clinical and commercial advancements. As a long-term believer deeply engaged in China's healthcare industry, Gortica Investment firmly believes in the vast prospects of the healthcare sector. It will continue to identify innovative enterprises that truly meet clinical needs and deliver value, supporting more outstanding healthcare companies to grow rapidly.

01
Beijing Mabworks Biotechnology Co.,Ltd: Second New Drug Application for MIL62‍‍‍‍‍‍
NDA for the Treatment of Primary Membranous Nephropathy Accepted‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍

Recently, Beijing Mabworks Biotechnology Co., Ltd. announced that the New Drug Application (NDA) for MIL62, its self-developed innovative third-generation CD20 antibody for the treatment of Primary Membranous Nephropathy (PMN), has been accepted by the National Medical Products Administration, becoming the world's first NDA-submitted drug targeting PMN treatment.。‍‍‍

As of now, no specific drug for the treatment of PMN has been approved by pharmaceutical regulatory agencies worldwide, with multiple innovative drugs currently in clinical trial development. The Phase III clinical trial of Beijing Mabworks Biotechnology Co., Ltd's MIL62 for PMN completed its primary endpoint analysis in July 2025. This clinical trial is the world’s first registrational study on PMN to reach its clinical endpoint, providing prospective randomized controlled evidence-based clinical data for global PMN clinical practice.

Previously, MIL62 for the treatment of PMN has been designated as a "breakthrough therapy" drug by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), and it is the first in chronic kidney disease.Therapeutic Area Obtains This Designation for Domestically Produced Drugs.In May 2025, the first MIL62NDA Application for New Drug Launch——The indication for Neuromyelitis Optica Spectrum Disorder (NMOSD) has been accepted by the CDE and included in the "Priority Review" list, and is currently under review.

02
TowardPi Medical: Officially Completes E+ Round of Financing‍‍‍‍
Focusing on High-End Ophthalmic Equipment, Looking Forward to the High-End Market Across Departments‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍

Recently, TowardPi announced the official completion of its E+ round of financing, jointly invested by Beijing Jingguan Equity Investment Fund, under Beijing State-owned Capital Operation and Management Co., Ltd., and Shuimu Ventures.This is the second financing deal completed within the year following the company's RMB 500 million Series E funding round earlier this year.‍‍‍

Relying on TowardPi's strong independent R&D capability for core components and its excellent market reputation, in the first three quarters of 2025, according toProcurement Data Express has announced ophthalmic equipmentBidding Information Statistics, TowardPi and Imported ProductsZEISS becomes a manufacturer in the Chinese marketThe Only TwoIn the four major productsLines (surgical microscopes, OCT, ultra-wide-angle cameras, biometers) have all entered the top five brands in market share.

In the first three quarters of 2025, TowardPi's ophthalmologyOCTProductRetain the titleTotal Amount and Total Number of Units Awarded"Double First", the market share of the winning bid reached 38.7%, further expanding its leading advantage. In terms of overseas expansion, since obtaining CE certification in 2024, TowardPi's OCT overseas sales have quickly surpassed 100 units, with its market share ranking among the top five in the European market during the same period, and the average selling price ranking first in the European market. As the company's second growth curve, ophthalmology...Surgical MicroscopeIn the first three quarters of this year, the total bid amount ranked fourth in the industry (the top three were all imports),The average winning bid reached452.9RMB 10,000, ranking first in the industry, among whichRepresenting High-End Models Produced in ChinaTowardPi's "Boyun" series has historically entered the top ten of the sub-model ranking list for the first time; the total bid amount in the industry for ultra-wide-angle fundus cameras and biometers has also reached the fourth and third positions in the industry, respectively, perfectly completing the product mission of filling the pipeline completeness. The research and development of products such as phacoemulsification and vitrectomy machines, neurosurgical operating microscopes, and femtosecond laser cataract surgery systems are all proceeding steadily, and they are expected to be launched successively within the next 2-3 years.

03
Xinkanghe: Announces XKH001 at ERS 2025‍‍‍‍‍‍XKH001
Clinical Research Results of lc Phase in Asthma Patients‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍

Recently, Xinkanghe Biopharmaceuticals, an innovative immunology drug development company, presented the Phase Ic clinical research results of XKH001, the world's first (First in Class) anti-IL-25 monoclonal antibody, in a poster session at the European Respiratory Society Annual Congress 2025 (ERS 2025).‍‍‍

This is an open-label, single-arm, Phase Ic clinical trial that enrolled 12 patients with mild allergic asthma. Subjects underwent methacholine challenge tests and received subcutaneous injections of XKH001 every four weeks. The results showed that in allergic asthma patients with moderate to severe baseline airway hyperresponsiveness (AHR) induced by methacholine, XKH001 treatment increased PD20-FEV1. This study provides the first clinical evidence supporting IL-25 as a therapeutic target for patients with moderate to severe asthma.

XKH001 is the world's first drug targeting IL-25 to enter clinical trials (approved by both the US FDA and China NMPA), while other similar drugs globally are still in the preclinical research stage. In China, XKH001 in healthy individuals...Stage Ia, SAD,Stage IbMAD and in Asthma PatientsPhase IcThe clinical trial has been completed, and the results of the above clinical studies have demonstrated its good efficacy, pharmacokinetic properties, and safety. XKH001 has currently received IND approval for indications such as asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF). A Phase II clinical study for atopic dermatitis (AD) is being conducted in China, and Phase II clinical studies for other indications will be carried out successively.

04
Rosunbot: The First Rosun Multimodal System in China®‍‍‍‍‍‍
Installation Ceremony of Intelligent Orthopedic Surgery Robot Held in Beijing‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍

Recently, the "National Public Hospital Reform and High-Quality Development Demonstration Project: Clinical Application of Fracture Reduction Robot Technology" hosted by the Beijing Regional Integration Management Committee of China General Health and undertaken by the Aerospace Center Hospital has been implemented. This marks the launch of the world's first Rosen Universal Phase system.® Intelligent Orthopedic Surgery Robot Installation Ceremony" Grandly Held at the Sujiatuo Campus of Beijing Aerospace Center Hospital。‍‍‍

As the highlight of the ceremony, the first Rosen Wanxiang® intelligent orthopedic surgery robot in China — and globally — was officially installed. This product, fully independently developed by RosenBot, features globally innovative reduction path planning and real-time navigation capabilities, enabling precise minimally invasive reduction of complex fractures such as those of the pelvis and long bones.

Compared with traditional surgery, this world-first product utilizes advanced digital intelligence algorithms (capable of rapidly planning reduction paths within three minutes); a robust robotic arm with a load capacity of 160N (precise, smooth, and consistent operation under heavy loads), enabling full robotic participation and automatic achievement of sub-millimeter precision in closed reduction. It achieves a 100% success rate and over 95% excellent/good rate in closed reduction, with position accuracy less than 1.0mm and angular accuracy less than 1°. The product reduces surgical risks, shortens recovery and hospitalization time, while also decreasing radiation exposure for both patients and medical staff. Additionally, it offers significant advantages for elderly patients with pelvic fractures, having successfully performed minimally invasive robotic reduction treatments on multiple patients aged over 80 (the oldest being 92 years), overcoming clinical challenges in minimally invasive treatment for elderly pelvic fracture patients. Moreover, the product demonstrates excellent clinical efficacy for critically ill patients, having successfully conducted minimally invasive robotic reduction treatments on more than ten patients with severe multiple pelvic injuries, effectively enhancing emergency MDT treatment capabilities.

05
Chenglian Technology: Selected as a "Potential Unicorn Enterprise in Jiangsu Province"‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍

Recently, the "2025 Jiangsu Unicorn and Gazelle Enterprises Evaluation Results Release Conference" was grandly held in Nanjing, officially unveiling the heavyweight list of the year.Chenglian Technology has successfully been rated as a "Jiangsu Province Potential Unicorn Enterprise" with its hardcore technological strength and excellent industrialization progress in the field of removable dentures.‍‍‍

Since its establishment, Chenglian Technology has always focused on reshaping the removable denture industry through technological innovation. The company has built a complete digital manufacturing ecosystem for removable dentures around the cutting-edge technology of "dental 3D printing," covering raw materials, software, equipment, and services, driving the industry's digital transformation and intelligent upgrade. Meanwhile, the company implements a dual-brand strategy in both international and Chinese markets with "Yakemei" and "Formeta Dental," aiming to comprehensively enhance the quality of removable denture manufacturing and set a new benchmark for the industry.

The company has successively developed metal printing materials, stent intelligent design software, and dental-specific metal 3D printers with independent intellectual property rights.Related post-processing equipment, achieving full coverage of key production环节 for removable dentures, with the future potential to realize integrated design and production of removable dentures. Meanwhile,The company has innovatively launched a distributed manufacturing cloud platform that combines "Internet + 3D printing." Global dental factories only need to send task requests through the Chenglian Cloud Platform. The platform's digital design team can perform industrial CAD design and data processing online. The intelligent production scheduling system of the cloud platform assigns printing tasks to the optimal cloud factory for production. Finally, the products are quickly delivered through the smart logistics system.In the user's hands.

Chenglian Technology adheres to a global strategic layout, building a sales network covering multiple countries and regions worldwide, establishing localized and digital manufacturing bases, and accelerating the expansion in overseas markets. To date, Chenglian Technology has set up digital centralized manufacturing bases in over 30 countries and regions, including Germany, the United States, Canada, France, and South Korea. It produces more than 10,000 active brackets daily, serving over 1,500 denture factories. The majority of China's top 1,000 denture factories are clients of Chenglian Technology.

06
Kunyu BioColonAiQ® Officially Approved for Use in Thailand
New Technology for Early Detection of Colorectal Cancer Accelerates Promotion in the Asia-Pacific Region‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍

Recently,Singlera Bioscience and Thai partner ARTBiotech jointly announced:Kunyu BiotechColonAiQ, a self-developed colorectal cancer detection product® Multi-Gene Methylation Detection Kit Officially Receives Thai FDA Registration Approval (Registration No.: 68-2-2-1-0010537). This approval marks ColonAiQ®Following its successful registration in Singapore this past April, it has once again taken a crucial step towards internationalization.‍‍‍

ColonAiQ® analyzes multi-gene methylation markers in the blood and combines fluorescent probe quantitative PCR technology to efficiently identify the risk of colorectal cancer and precancerous lesions, while monitoring the postoperative recurrence risk in patients with stage I-III colorectal cancer. Compared with traditional imaging or proteomic methods, this technology utilizes the characteristics of circulating tumor DNA (ctDNA) to achieve non-invasive, real-time, and highly sensitive detection, providing a more convenient and precise solution for clinical practice.Solution, to support early diagnosis and treatment of cancer as well as postoperative management.

This time ColonAiQ®The landing in Thailand not only brings better testing options for patients in Southeast Asia but also marks that Singlera Genomics continues to lead the liquid biopsy track in global layout, using technological innovation to support cancer prevention and treatment, safeguarding the future of human health.

07
Henlius: The World's First H Drug for Perioperative Gastric Cancer
Phase III Clinical Study Meets Primary Endpoint‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍‍

Recently, Henlius (2629.HK) announced that its self-developed innovative PD-1 inhibitor H drug Hansizhuang® (Sulrilizumab, European trade name: Hetronifly)®) The interim analysis of the Phase III clinical study (ASTRUM-006) for neoadjuvant combination chemotherapy/adjuvant monotherapy in gastric cancer has reached the primary endpoint of Event-Free Survival (EFS). This becomes the world's first perioperative (preoperative/postoperative) treatment regimen in gastric cancer to replace postoperative adjuvant chemotherapy with immunotherapy alone, achieving a significant breakthrough in this field.‍‍‍

ASTRUM-006 is a randomized, double-blind, multi-center Phase III clinical study targeting patients with early-stage gastric cancer. It aims to evaluate the clinical efficacy and safety of Hansizhuang® combined with chemotherapy compared to placebo combined with chemotherapy as neoadjuvant/monotherapy adjuvant treatment for early-stage gastric cancer patients. According to the interim analysis results from the Independent Data Monitoring Committee (IDMC), the study met the pre-specified superiority criteria. Compared to placebo combined with chemotherapy, Hansizhuang® combined with chemotherapy significantly improved EFS, with the pathological complete response (pCR) rate being more than three times that of the control group, and the risk of recurrence was significantly reduced in patients. Meanwhile, this treatment regimen demonstrated good safety, with no new safety signals identified. Based on these positive results, it is recommended to file for marketing authorization ahead of schedule.

Henlius has proactively laid out a diversified, high-quality product pipeline covering approximately 50 molecules and is comprehensively advancing tumor immunotherapy combination therapies based on its proprietary anti-PD-1 monoclonal antibody H drug, Hansizhuang®. To date, the company's approved products include the world’s first anti-PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer, Hansizhuang® (serplulimab, European trade name: Hetronifly®), the self-developed monoclonal antibody biosimilar approved in China, the U.S., and Europe, Hanquyou® (trastuzumab, U.S. trade name: HERCESSI™, European trade name: Zercepac®), China’s first biosimilar Hanlikang® (rituximab), as well as the denosumab biosimilars Bildyos® and Bilprevda®. The company is also concurrently conducting over 30 clinical trials globally across 19 products, with out-licensing fully covering mainstream biopharmaceutical markets in Europe and the U.S., as well as numerous emerging markets.

About Gortec Investment

GaoTJ Investment was founded in Shenzhen in 2001. It was the first in the industry to propose the investment model of "thematic industry investment," focusing on healthcare industry investments. It is led by strategic equity investments and covers all investment stages, including VC, PE, Pre-IPO, and M&A. With a professional investment team that is among the few in China deeply focused on the healthcare track, it has built an investment ecosystem platform for the healthcare industry, aiming to become a healthcare investment institution with global influence.

Gortica Investment's asset management scale exceeds 23 billion RMB, with 35 healthcare industry funds. It has invested in over 110 healthcare enterprises and facilitated the successful listing of 41 companies including Mindray Medical, United Imaging Healthcare, and Akeso Biopharma. Gortica Investment operates in China and globally, establishing operational centers in Shenzhen, Shanghai, Beijing, Hong Kong, and other locations. It is committed to investing in outstanding healthcare enterprises worldwide, creating new development opportunities for global capital and medical companies, and assisting entrepreneurs in building great enterprises.